Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.

Alison C BackenAndre LopesHarpreet WasanDaniel H PalmerMarian DugganDavid CunninghamAlan AnthoneyPippa G CorrieSrinivasan MadhusudanAnthony MaraveyasPaul J RossJustin S WatersWilliam P StewardCharlotte ReesMairéad G McNamaraSandy BeareJohn A BridgewaterCaroline DiveJuan W Valle

Published in: British journal of cancer (2018)

Rising circulating VEGFA levels in patients with ABC, treated with CisGem, are associated with worse PFS and OS, not seen in patients receiving cediranib. Rising levels of markers of tumour burden (CK18) and potential resistance (VEGFR2) are associated with worse outcomes and warrant validation.

Keyphrases

papillary thyroid
phase iii
squamous cell
squamous cell carcinoma
type diabetes
cross sectional
risk factors
protein kinase
metabolic syndrome
human health
skeletal muscle
lymph node metastasis